A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
171actual
Sites
33
Countries
Canada, China, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-24 | actual | When the study began enrolling |
| Primary completion | 2026-01-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-22 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Interventions
- Drug: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate
- Drug: Treatment B: Budesonide and Formoterol Fumarate
- Drug: Treatment C : Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in isotime Inspiratory capacity (IC)
measured 2 weeks post-treatment
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed